Enorama Pharma AB (ERMA)
Stockholm Exchange · Sweden · prices in SEK · close of 19 Oct 2026
Key indicators
| Last close | SEK 0.992 |
|---|---|
| 52-week range | 0.211 – 3.000 |
| Return, 1 month / 3 months | +43.8% / +184.2% |
| Return, 1 year / 3 years | −61.1% / −69.9% |
| Trend | Uptrend |
| RSI (14) | 61 |
| Volatility (1 year) | 229.9% |
| Worst drawdown (1 year) | -91.5% |
| Average daily value traded | 0.22M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
Summary
Enorama Pharma AB (ERMA) trades on the Stockholm Exchange in Sweden. It last closed at SEK 0.992 on 19 October 2026.
Its price-based Market X-Ray is 44 out of 100 (a weak price profile), ranking 567 of 911 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 61.1% and over the last three months it rose 184.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 62 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 42.7% | ||
| From 52-week high | -66.9% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 184.2% | ||
| 6-month return | 158.3% | ||
| 12-month return, skipping the last month | -72.9% | ||
| Stability (higher is calmer) | 3 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 229.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -91.5% | ||
| Liquidity | 40 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.22M SEK | ||
| Zero-volume days | 3.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +80.4% |
|---|---|
| 1 month | +43.8% |
| 3 months | +184.2% |
| 6 months | +158.3% |
| 1 year | −61.1% |
| 3 years | −69.9% |
| 5 years | – |
Signals
| 50-day / 200-day average | 0.748 / 0.695 |
|---|---|
| Golden / death cross (60 days) | Golden, 2 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.231 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.